Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

C3.ai

Arista Networks

American Express

GitLab

Monolithic Power Systems

Microsoft

NVIDIA

Novo Nordisk

Royal Caribbean Cruises

Arista Networks, which keeps popping up on lists of top AI stocks, leads this weekend's watch list of 5 stocks near buy points. The post AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam appeared first on Investor's Business Daily.

AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam

Best Buy

Salesforce

Here are seven major companies whose stocks moved on the week's news.

Best Buy, Eli Lilly, Salesforce: Stocks That Defined the Week

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor  size, and  tumor grade , regardless of Ki-67 score Approval supported by  four-year data from the monarchE trial; Verzenio added to adjuvant endocrine therapy (ET) reduced the risk of recurrence by 35% compared to adjuvant ET alone   Verzenio remains the first and only CDK4/6 inhibitor approved in the adjuvant setting INDIANAPOLIS , March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that are ≥5 cm or Grade 3).1 This expanded adjuvant indication removes the Ki-67 score requirement for patient selection.

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

Established companies in industries less vulnerable to cyclical headwinds can offer a measure of safety in a market storm.

2 Safe Stocks to Buy Hand Over Fist in 2023

AbbVie

Amazon

Chevron

Alphabet

Johnson & Johnson

PepsiCo

Tesla

After a strong performance in January, the stock market lost pace in the second month of the year.

5 Best and Worst Performing Mega-Cap Stocks in February 2023

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

These top growth stocks sport premium valuations for a very good reason.

3 Incredible Growth Stocks to Buy if the Market Dips

Intuitive Surgical

Investors might want to act fast before it's too late.

2 Stocks Down 12% or More This Year to Buy Hand Over Fist

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lilly and Company for Confo's clinical stage CFTX-1554 and back-up compounds.

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

The changes could help around 2 million people pay for the life-sustaining drug.

Eli Lilly to slash prices for insulin drugs by 70%

Eli Lilly's announcement that it will cut the price of insulin for people with commercial health insurance — capping out-of-pocket insulin costs to $35 — highlights just how much money people are paying on these injections.

Eli Lilly CEO says $35 for monthly insulin ‘should be the new standard in America'

Eli Lilly announced a 70% price cut for most of its insulins Wednesday in a move its CEO described as "aggressive." Eli Lilly stock jumped.

Diabetes Giant Eli Lilly Slashes Insulin Prices 70% In A Move Its CEO Calls 'Aggressive'

The drugmaker says it's also cutting prices by 70% for its most commonly prescribed insulins.

Eli Lilly to Cap Out-of-Pocket Cost of Insulin to $35 a Month for Many People

Eli Lilly and Co (NYSE:LLY) announced it is reducing the price of most of its commonly prescribed insulins by 70% and the expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month following criticism of the pharmaceutical giant over the high price of its insulin products from lawmakers and advocacy groups. The move also comes after US President Joe Biden's Inflation Reduction Act capped insulin at $35 for Medicare Part D enrollees, effective January 1, 2023, with a similar cap to take effect for enrollees in Medicare Part B on July 1, 2023.

Eli Lilly to cut insulin prices by 70%

Here's a positive news item for U.S. insulin users. Drugmaker Eli Lilly (NYSE: LLY ) just revealed that it's reducing the cost of its most commonly prescribed insulin products by 70%.

LLY Stock Alert: Eli Lilly Slashes Insulin Prices, Caps Patient Costs

Move comes amid criticism of healthcare companies over rising costs of insulin, as CEO says cuts ‘should be the new standard'

Drugmaker Eli Lilly says it will cut insulin prices by 70%

Eli Lilly said it will cut the price of its insulins by 70% and cap out-of-pocket prices. But Eli Lilly stock was muted Wednesday.

Diabetes Behemoth Eli Lilly Slashes Insulin Prices By 70%

Eli Lilly & Co. LLY said Wednesday that is capping out-of-pocket insulin costs to $35 for people with commercial health insurance at certain retail pharmacies and it is also lowering the prices of most its insulins, such as pricing non-branded Insulin Lispro at $25 a vial. The company also plans to cut the list price of Humalog and Humulin in the fourth quarter, though it did not say by how much.

Lilly to cut price of insulin for people with commercial health insurance

Drugmaker Eli Lilly & Co. on Wednesday said it will cut prices of its most commonly prescribed insulins by 70% and cap monthly prices at $35 per month at certain retail pharmacies for people who have private insurance.

Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance

Eli Lilly and Co said on Wednesday it would reduce prices by 70% for its most commonly prescribed forms of insulin.

Lilly to cut insulin prices by 70% from fourth quarter

INDIANAPOLIS , March 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable insulin.

Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month

Facing pressure to curb diabetes-treatment costs, the company will cut the list prices for its most commonly prescribed insulin and take other steps to make it easier for patients to afford the drugs.

Eli Lilly to Cut Prices of Insulin Drugs by 70%

Newamsterdam Pharma Co NV

Cassava Sciences Inc

One in every nine seniors is living with Alzheimer's disease, and the race to cure it is worth big money. While the FDA has approved some Alzheimer's disease drugs, these can only slow the progression, not halt or reverse it.

3 Drug Stocks to Watch as Alzheimer's Clinical Trials End

Broadcom

Mondelez

Philip Morris

Raytheon Technologies

Visa

Many long-term investors appreciate dividend stocks, for many reasons. Companies that pay back a portion of their profits to their shareholders via dividends are generally more reliable.

7 Dynamite Dividend Stocks for Income and Growth in 2023

Eli Lilly and Company (NYSE: LLY) is one of the most recognized names in the pharmaceutical industry. Indeed, they are the 12th-largest pharmaceutical company in the world by revenue ($5.5 billion in 2021), and its balance sheet reads as such.

Analyst Confidence in Eli Lilly Boosted by Product Pipeline

Lockheed Martin

Verizon

These three defensive stocks could cushion your portfolio from market volatility this year.

News for Eli Lilly Stock (LLY)